First on the ASX - BOD announces successful outcome for insomnia clinical trial
Wise-Owl
Sep 06, 2023
Our investment, BOD Science (ASX: BOD), has successfully demonstrated the statistical efficacy of its 100mg CBD product for treating insomnia in a Phase IIb study. This milestone puts BOD on track to be the first Australian company to offer a CBD-based insomnia treatment over-the-counter.
